Emerging Company Profile

<div class="articleContainer"><div class="articleWrapper"><div class="articleContent"><h1 class="text title">Wound-up bacteria</h1><h2 class="title-bottom webtitle">Ilya delivers CXCL12 via engineered bacteria to speed wound healing</h2><div class="byline">Sandi Wong, Staff Writer</div><div class="date"></div></div></div></div>

Ilya Pharma AB

Swedish University of Agricultural Sciences

Uppsala University

Wounds

ILP100

Chemokine CXC motif ligand 12 (CXCL12) (SDF-1)

Dipeptidyl peptidase-4 (DPP-4) (CD26)

Wound-up bacteria

Ilya is engineering bacteria to stimulate wound closure as a more convenient and cheaper alternative to growth factor therapies.

Ilya delivers CXCL12 via engineered bacteria to speed wound healing

Featured Analysis

Articles by Category

Current Editions

Data Graphics

Distillery

Podcasts & Webcasts

Special Reports & Presentations

White Papers

Analysis

BCIQ

Company Profiles

Product Profiles

Target Profiles

Financial Dashboards

BCIQ Data

All Events

China Healthcare Summit

Bio€quity Europe

The BioCentury Show

Events

My Workspace

Company Overview

Management

Analysts & Research Team

Scientific Advisory Board

About BioCentury

Contact Us

Forgot Password

Trial

Subscribe

Advertising & Sponsorship

Career Opportunities

Customer Resource Center

Contact

Home

<br/><br/><center><span style="font-size:1.75rem;font-weight:500;">Access this Article</span></center>